Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Pancreatic Cancer|Breast Cancer|Gastric Cancer|Non-small Cell Lung Cancer|Cervical Cancer|Endocervical Cancer|Squamous Cell Carcinoma of Head and Neck|Bladder Urothelial Cancer|Colorectal Carcinoma|Esophageal Cancer|Ovarian Cancer|Renal Cell Carcinoma|Prostate Cancer|Melanoma|Mesothelioma|Cholangiocarcinoma
Interventions: DRUG: NGM831|DRUG: NGM831 plus pembrolizumab (KEYTRUDA®)|DRUG: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Sponsor: NGM Biopharmaceuticals, Inc
Collaborators: Merck Sharp & Dohme LLC